Biden Administration Rescinds Trump Administration Insulin …
WEBOct 26, 2021 · One of the final healthcare actions made by the Trump Administration has been rescinded by the Biden Administration. On December 23, 2020, the Trump Administration finalized a rule that directed the Department of Health and Human Services (HHS) to take action to require that federally qualified health centers (FQHCs) make insulin and injectable epinephrine available to certain patients at 340B ...
Policy & Medicine – Legal, Regulatory, and Compliance Issues
WEBHHS OIG Issues Report on Two Midnight Rule in Medicare. CMS estimates that between 2017 and 2021, Medicare Part A improperly paid $23.9 billion for inpatient hospital stays, with $7.8 billion attributable to short stays that did not qualify for Medicare Part A. On June 13, 2024, the U.S. Department of Health and Human Services’ Office of ...
Institute of Medicine Report – The Future of Nursing: Leading …
WEBFeb 17, 2011 · As the current debate surrounding the Affordable Care Act (ACA) continues in Congress, a number of strengths and weaknesses of the legislation are being emphasized. One specific issue is how the American …
Physician Payments Sunshine Act Final Rule: Quick Reference Guide
WEBFeb 13, 2013 · The total amount of civil money penalties will not exceed $150,000. Knowingly failing to submit payment information will result in a civil money penalty of not less than $10,000, but not more than $100,000, for each payment. The penalty will not exceed $1,000,000. Combined, penalties may not exceed $1,150,000.
Medtronic Settles $2.8 Million Off-Label Suit Over Neurostimulator ...
WEBFeb 11, 2015 · 31,522. Minnesota-based medtech company, Medtronic Inc., has agreed to pay $2.8 million to resolve allegations that the company promoted its neurostimulator device for unapproved chronic pain treatment. According to the complaint, originally filed by former Medtronic sales rep Jason Nickell, Medtronic sales staff were directed to sell the ...
CMS Updates Guidance on Sunshine Act Reporting Thresholds for …
WEBJan 25, 2021 · At the end of 2020, the Centers for Medicare and Medicaid Services (CMS) issued updated guidance on the thresholds that require an Applicable Manufacturer or Group Purchasing Organization to report under the Sunshine Act. Under the new guidance, if an Applicable Manufacturer or Group Purchasing Organization spends $11.05 or more on a “Reportable Activity” for any Covered Recipient from ...
PhRMA Announces Updated Code on Interactions with Health …
WEBOn August 6, 2021, the Pharmaceutical Research and Manufacturers of America (PhRMA) released its updated Code on Interactions with Health Care Professionals, a voluntary code of ethics that applies to pharmaceutical company interactions with United States health care professionals. As a member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the PhRMA ...
California Enacts Legislation on Reporting of Prescription Drug Costs
WEBOct 2, 2017 · California’s Senate and Assembly have both passed legislation on publishing prescription drug prices (SB-17) and presented the legislation to California Governor Jerry Brown on September 19, 2017. Under California law, the Governor has twelve days to sign or veto the legislation before it becomes law automatically.
CMS April 2022 Update to Open Payments FAQs - Policy & Medicine
WEBApr 18, 2022 · CMS Open Payments. By Thomas Sullivan Last updated Apr 17, 2022. On April 12, 2022, the Centers for Medicare and Medicaid Services (CMS) announced a revised version of the Open Payments Frequently Asked Questions (FAQs). While the revision includes some minor grammatical changes, CMS also removed a handful of FAQs and added nine new FAQs.
FDA Issues Draft Guidance on Proprietary Names
WEBFeb 2, 2021 · The U.S. Food and Drug Administration (FDA) issued a pair of draft guidance documents aimed at guiding the selection of proprietary names for prescription and non-prescription drugs. The best practices set forth in the guidances are designed “to help minimize proprietary name-related medication errors and otherwise avoid adoption of ...